ASSURE
Adapting Breast Cancer Screening Strategy Using Personalised Risk Estimation
| Coordinatore | STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Sito del progetto | http://www.assure-project.eu |
| Totale costo | 7˙235˙026 € |
| EC contributo | 5˙608˙543 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-12-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | coordinator | 1˙048˙127.20 |
| 2 |
MEVIS MEDICAL SOLUTIONS AG
Organization address
address: UNIVERSITAETSALLEE 29 contact info |
DE (BREMEN) | participant | 796˙125.60 |
| 3 |
BIOMEDIQ AS
Organization address
address: FRUEBJERGVEJ 3 contact info |
DK (KOBENHAVN) | participant | 700˙086.80 |
| 4 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 687˙413.60 |
| 5 |
MATAKINA UK LIMITED
Organization address
address: WALNUT TREE CLOSE 1 contact info |
UK (ELY) | participant | 631˙680.75 |
| 6 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 566˙798.75 |
| 7 |
Medical Imaging Research Institute
Organization address
address: Vangerowstr. 18 contact info |
DE (Heidelberg) | participant | 404˙360.00 |
| 8 |
UNIVERSITAT DE GIRONA
Organization address
address: PLACA SANT DOMENEC 9 EDIFICI LES ALIGUES contact info |
ES (GIRONA) | participant | 355˙290.40 |
| 9 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 263˙095.20 |
| 10 |
Institut Jules Bordet
Organization address
city: Brussels contact info |
BE (Brussels) | participant | 155˙565.20 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'While early detection of breast cancer by screening appears effective, many women derive little or no benefit from screening, due to the way it is currently organized: as a one-size-fits all approach irrespective of personalised risk factors. It is known, however, that some women are at a much higher risk of getting the disease than others, and that mammography is unsuitable for cancer detection in women with dense breasts. The aim of this project is to develop personalised methods to tailor breast cancer screening to the individual needs of the woman. We will propose methods to stratify women at the highest risk to MRI; those with intermediate risk and/or dense breasts to follow-on ultrasound. A risk model will be developed that includes both breast cancer risk and the risk of missing cancers in mammograms. In this model, breast density plays a key role, as one of the largest known risk factors and the factor making mammograms ineffective. Two SMEs focusing on breast density are involved, where academic partners bring unique databases with over 80,000 screening mammograms and associated risk profiles. These are essential for model development, and subsequently for the development of products that benefit all women. Personalised screening is only economically feasible if it is based upon cost-effective strategies. While current methods in breast MRI imaging and breast ultrasound are promising, more efficient protocols must be developed to use these modalities routinely in screening. With leading SMEs and clinical partners, screening procedures will be optimized by developing automated image analysis tools to guide workflow and quality assurance. More efficient MRI protocols will be investigated to reduce time and cost, while the use of novel MRI imaging sequences without intravenous contrast will be explored. Cost-effectiveness of the stratification models will be assessed by combining the risk model with cost and effectiveness of alternative screening strategies.'
Altri progetti dello stesso programma (FP7-HEALTH)
MYASTERIX (2013)
"Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis"
Read More